Pseudo-Generic Products and Barriers to Entry in Pharmaceutical Markets

Ying Kong and James R. Seldon

Review of Industrial Organization, 2004, vol. 25, issue 1, 86 pages

Abstract: This paper examines incentives for brand-name pharmaceutical producers to market pseudo-generic versions of their own branded products upon the expiry of patent protection.Using a two-stage game model, we determine that under plausible demand and cost conditions, brand-name incumbents can find it profitable to produce pseudo-generics as a means of blocking rivals' entry even when independent firms producing true generics face low entry costs.The model shows that social welfare can be higher when firms use pseudo-generics instead of capacity for entry deterrence as long as substitutability between brand-name and generic products is sufficiently high.

Date: 2004
References: Add references at CitEc
Citations: View citations in EconPapers (20)

Downloads: (external link)
http://journals.kluweronline.com/issn/0889-938X/contents (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:kap:revind:v:25:y:2004:i:1:p:71-86

Ordering information: This journal article can be ordered from
http://www.springer. ... on/journal/11151/PS2

Access Statistics for this article

Review of Industrial Organization is currently edited by L.J. White

More articles in Review of Industrial Organization from Springer, The Industrial Organization Society Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().